GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARNF) » Definitions » Total Current Liabilities

Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Total Current Liabilities : $4.85 Mil (As of Dec. 2018)


View and export this data going back to 2014. Start your Free Trial

What is Parnell Pharmaceuticals Holdings Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Parnell Pharmaceuticals Holdings's total current liabilities for the quarter that ended in Dec. 2018 was $4.85

Parnell Pharmaceuticals Holdings Total Current Liabilities Historical Data

The historical data trend for Parnell Pharmaceuticals Holdings's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parnell Pharmaceuticals Holdings Total Current Liabilities Chart

Parnell Pharmaceuticals Holdings Annual Data
Trend Jun12 Jun13 Jun14 Dec15 Dec16 Dec17 Dec18
Total Current Liabilities
Get a 7-Day Free Trial 9.52 7.49 6.25 6.68 4.85

Parnell Pharmaceuticals Holdings Semi-Annual Data
Jun12 Jun13 Jun14 Dec15 Dec16 Dec17 Dec18
Total Current Liabilities Get a 7-Day Free Trial 9.52 7.49 6.25 6.68 4.85

Parnell Pharmaceuticals Holdings Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Parnell Pharmaceuticals Holdings's Total Current Liabilities for the fiscal year that ended in Dec. 2018 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=4.282+0.007
+Other Current Liabilities+Current Deferred Liabilities
=0.56+0
=4.85

Parnell Pharmaceuticals Holdings's Total Current Liabilities for the quarter that ended in Dec. 2018 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=4.282+0.007
+Other Current Liabilities+Current Deferred Liabilities
=0.56+0
=4.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Parnell Pharmaceuticals Holdings Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Parnell Pharmaceuticals Holdings's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARNF) » Definitions » Total Current Liabilities
Comparable Companies
OWCP CXUS CANB CNABQ LITH APPB GSRX PCYN EVIO GENH ZTS TSE:4502 XTER:MRK HKSE:03692 TSE:4523 SZSE:000661 TSE:4507 SZSE:000538 NSE:SUNPHARMA SZSE:300601
Traded in Other Exchanges
N/A
Address
476 Gardeners Road, Unit 4, Century Estate, Alexandria, Sydney, NSW, AUS, 2015
Website
https://www.parnell.com
Parnell Pharmaceuticals Holdings Ltd is an Australia based veterinary pharmaceutical company. It is focused on developing, manufacturing and commercializing animal health solutions. The group manufactures and market products for companion animals and production animals. The firm also has a pipeline of drug products like Zydax, PAR121 and PAR122 and Luminous which covers therapeutic areas in orthopedics, dermatology, and nutraceuticals. The operating segments of the company are Companion animal, Production animal - U.S., Production animal - rest of world and Contract Manufacturing. It operates internationally and generates the majority of the revenue from the Production animal - U.S. segment which covers the group's reproductive hormone portfolio across production animal in the USA.

Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Headlines

From GuruFocus

Notice of Annual General Meeting and Explanatory Memorandum

By ACCESSWIRE AccessWire • 04-12-2019

Parnell Pharmaceuticals Gives Notice of Annual General Meeting and Explanatory Memorandum

By ACCESSWIRE • 11-06-2023

Parnell Pharmaceuticals Holdings Ltd Announces Commencement of Rights Offering

By PRNewswire PRNewswire • 12-07-2022

Parnell Pharmaceuticals Gives Notice of Annual General Meeting and Explanatory Memorandum

By ACCESSWIRE ACCESSWIRE • 07-14-2021

Parnell Pharmaceuticals Holdings Ltd Announces Extension of Rights Offering

By PRNewswire PRNewswire • 01-06-2023

DW Healthcare Partners Invests in Parnell

By PRNewswire PRNewswire • 02-02-2021

Notice of Annual General Meeting and Explanatory Memorandum

By ACCESSWIRE AccessWire • 04-30-2019

Results of Annual General Meeting of Shareholders Held May 31, 2018

By ACCESSWIRE AccessWire • 04-12-2019

DWHP Announces Extension of The Expiration Time of Its Tender Offer

By PRNewswire PRNewswire • 01-22-2021

Parnell Pharmaceuticals Holdings Completes Debt Refinancing With Marathon Asset Management

By ACCESSWIRE AccessWire • 04-12-2019